Scienta’s Post

Recording Now Available 👉 https://lnkd.in/ebKqMHBe Many modern therapies, particularly in oncology and immunology, work within complex tissue environments, yet biomarker strategies are often built from fragmented assays that measure isolated signals without capturing how biology functions at the tissue and cellular level. Learn how to build a successful biomarker strategy that results in: • Early validation of target relevance and mechanism of action (MoA) • Understanding of cell-type specificity, tissue heterogeneity and biological context • Identification of translational biomarkers that remain meaningful from preclinical to clinical stages • Strong rationale for biomarker down-selection prior to formal validation • Confidence in biomarker data used to support development decisions • Prevention of unanticipated late clinical failure caused by lack of efficacy

Uncover unique phenotypes and understand protein expression on a single-cell level with TotalSeq™! Proteogenomics is transforming how we approach precision medicine, oncology, and immunology. With TotalSeq™ oligo-conjugated antibodies from BioLegend, you can seamlessly integrate protein and RNA analysis into your existing sequencing protocols. Why choose TotalSeq™ for your research? - Reliability: Pre-titrated in single-use tubes to reduce inconsistencies from pipetting and handling. - Versatility: Grouped into TotalSeq™-A, -B, and -C for seamless platform and assay compatibility. - Depth: Ranging from Basic Immunophenotyping to deep exploratory phenotyping. Spotlight: Human Essential Cocktails V1.0. Available across all TotalSeq™ formats, these cocktails target 100 proteins, focusing on the most frequently cited markers for characterizing immune cell sub-lineages—essential for translational research and immuno-oncology. Ready to elevate your single-cell analysis? Discover more about TotalSeq™ antibodies here: https://lnkd.in/dM77wu5S

Why MHC-Peptide Complexes Are Becoming the Backbone of Precision Immunology MHC-peptide complexes have moved to the center of precision immunology because they determine what the immune system can truly “see.” These molecular displays sit on the cell surface and present peptide fragments to T cells, shaping immune recognition in cancer, infectious disease, autoimmunity, and transplant medicine. As interest in next-generation immunotherapies accelerates, the ability to identify, characterize, and target specific MHC-peptide interactions is becoming a strategic advantage for both research and clinical innovation. What makes this field especially important now is the convergence of immunopeptidomics, computational prediction, and engineered T-cell platforms. Researchers can increasingly map disease-relevant antigens with greater resolution, while biotech and pharma teams use that insight to design more selective vaccines, TCR-based therapies, and biomarker strategies. This is changing the conversation from broad immune activation to highly targeted intervention, where efficacy depends on understanding exactly which peptide is presented, by which MHC allele, and in what biological context. For decision-makers, the real opportunity lies in translating this complexity into scalable therapeutic value. Success will depend on integrating discovery, validation, and patient stratification into one coherent development strategy. MHC-peptide complexes are not just a scientific niche; they are becoming a foundational layer of immune-based product design. Organizations that build capabilities in this area today will be better positioned to lead the next wave of differentiated therapies tomorrow. Read More: https://lnkd.in/dBMj4Bqz #360iResearchInsights #marketresearch #ImmunologyResearch #Immunotherapy #TCellResearch #AntigenPresentation

I am very pleased to share the publication of this review article on precision chemotherapy in pancreatic ductal adenocarcinoma. It has been a true honour to contribute to this work alongside Gabriele Capurso, Ingrid Garajová, Cindy NEUZILLET, Luigi Carmine Leta and Michele Reni, whose clinical leadership and scientific vision continue to shape the field. Pancreatic cancer remains one of the most lethal malignancies, and despite advances in systemic therapies, chemotherapy is still the backbone of treatment across disease stages. What is increasingly clear, however, is that treatment selection can no longer rely on empirical choices alone. In this review, we discuss how therapeutic decision-making is progressively evolving toward a multidimensional and adaptive personalization strategy, integrating: • tumour molecular vulnerabilities • transcriptomic and phenotypic determinants of chemosensitivity • patient fitness and pharmacogenetics • dynamic biomarkers such as liquid biopsies • tumour microenvironment features • and emerging targeted therapeutic opportunities Precision in pancreatic cancer will not come from a single biomarker or a single technology. It will emerge from the integration of biology, clinical insight and innovative translational tools, allowing more rational use of chemotherapy, earlier identification of resistance, and smarter treatment sequencing. Ultimately, the goal is simple but ambitious: to treat the right patient, with the right strategy, at the right moment of the disease. #PancreaticCancer #PrecisionOncology #Chemotherapy #TranslationalResearch #Biomarkers #PersonalisedMedicine

#Congratulations to Mestag Therapeutics on securing $40 million to advance their pioneering work in fibroblast immunology 👏🔗 ➡️ https://lnkd.in/e2a36MrB With plans to progress their lead programme into the clinic, this marks an important step towards developing new therapies for cancers that are often resistant to treatment. A strong example of cutting-edge science translating into real potential for patient impact.

Excited to share our latest work, now accepted in the Journal of Translational Medicine. In this work, we investigated the proteomic landscape of colorectal liver metastases (CRLM) and how it relates to the histopathological response to preoperative chemotherapy. Using label-free mass spectrometry proteomics, we analyzed 33 metastases and identified 607 proteins differentially expressed between major, partial, and non-responders. Metastases showing a major response were characterized by enrichment of pathways linked to immune infiltration, extracellular matrix organization, complement activation, and stromal remodeling, while proteins involved in mitochondrial translation were reduced. These findings highlight distinct proteomic phenotypes associated with chemotherapy response, largely independent of the specific treatment regimen, and nominate candidate protein biomarkers for therapy efficacy in CRLM. Many thanks to the fantastic interdisciplinary team involved in this project. Especially to Agnes K. Böhm Oliver Klein #ColorectalCancer #LiverMetastases #Proteomics #CancerResearch https://lnkd.in/dQjsA3Kn

Join ABclonal Technology in this webinar that explores tools that support more accurate immune profiling and biomarker analysis in non-human primate (NHP) preclinical research. NHP models are critical for immunology and therapeutic development, but validated reagents for NHP samples remain limited. Key topics include: • Why NHP models matter in preclinical studies • Current reagent gaps and challenges • ABflo® rabbit mAbs for NHP flow cytometry • ABplex® CBA kits for reliable NHP cytokine detection • Biomarker assessment in NHP biopsies using IHC and mIHC Who should attend: Preclinical researchers, immunologists, translational scientists, and CRO teams working with NHP models, especially those focused on flow cytometry, cytokine profiling, and biomarker discovery. Register here: https://lnkd.in/en34u9Xy #PreclinicalResearch #NonHumanPrimates #NHP #Immunology #Biomarkers #TranslationalResearch 

We are pleased to highlight that Stem Cell Science News offers a dedicated Human Immunology News platform, and that they are partnering with us for the 7th TCR Based Therapies Summit. Stay informed on autoimmunity and immunotherapy with the latest research, news, jobs, and events. Subscribe to Human Immunology News for free! https://bit.ly/4cBdiyR

🌍 Breakthrough Clinical Trials You Shouldn’t Miss — March 2026 The pace of innovation in clinical research continues to accelerate. Here are some of the most impactful trial updates from credible global sources this month 👇 💉 CD40 Intratumoral Injection — In a Phase 1 trial of 12 metastatic cancer patients, 6 saw tumours shrink and 2 experienced complete remission — even tumours that weren't injected disappeared, suggesting a body-wide immune response was triggered CAS (Cancer Cell / ScienceDaily) ✂️ CRISPR for Hereditary Angioedema — Intellia is expecting Phase 3 results from lonvo-z, billed as a potential "functional cure" that could eliminate the need for frequent injections or pills used to prevent attacks MIT Technology Review (BioPharma Dive) 🧠 Tolebrutinib for MS — The HERCULES Phase 3 trial showed tolebrutinib significantly delayed 6-month confirmed disability progression by 31% versus placebo — and it is the first BTK inhibitor reviewed for non-relapsing secondary progressive MS NPR (NeurologyLive) 🩺 Vertex's Lab-Grown Islet Cells for T1D — All 12 recipients in the zimislecel trial are off external insulin or on target to stop external insulin PR Newswire (Breakthrough T1D / ATTD 2026) 🎯 Gedatolisib in Breast Cancer — Results showed "unprecedented" reductions in risk of disease progression or death, with a rolling marketing application already filed in the US Nature (Pharmaphorum / Clarivate) #ClinicalResearch #ClinicalTrials #Biotech #CRISPR #Oncology #Diabetes #MultipleSclerosis #DrugDevelopment #HealthcareInnovation #IndiaResearch #Pharma

I am pleased to announce the opening of a new Special Issue, "Molecular Mechanism Influencing the Short- and Long-Term Toxicity of Cancer Treatments," in the journal Current Issues in Molecular Biology (Impact Factor: 3.0) 🧬. While advances in immunotherapy, chemotherapy, and radiation have transformed cancer survival rates, the resulting toxicities continue to significantly impact long-term health. Understanding the molecular underpinnings of these side effects is essential for developing mitigation strategies that do not compromise anti-tumor efficacy 🔬. We invite original research and comprehensive reviews focusing on: Molecular mechanisms of short- and long-term toxicities in oncology 🧬 Role of oxidative stress, cell signaling, and mitochondrial dysfunction 🧪 Inflammation, apoptosis, and tissue remodeling in treatment-induced injury 🛡️ Risk factors and individual variability in toxicity susceptibility 📊 Side effects of immunotherapy, targeted drugs, and radiation therapy 💊 Emerging therapeutic strategies to mitigate treatment-induced side effects 🏥 Experimental and translational aspects of anticancer drug toxicity 📉 Guest Editor: Dr. Giorgio Attinà Submission Deadline: 31 October 📅 This Special Issue aims to characterize the complex pathways driving treatment-related morbidity and foster the discovery of protective interventions for cancer patients. Read the full scope and submission guidelines here: https://lnkd.in/ePBCgCb7 🔗 #Oncology #CancerResearch #DrugToxicity #MolecularBiology #Pharmacology #CancerSurvivorship #PrecisionMedicine #CallForPapers